A role for synaptic zinc in ProSAP/Shank PSD scaffold malformation in autism spectrum disorders

Developmental Neurobiology

Volumn 74, Issue 2, 2014, Pages 136-146

  Grabrucker, Andreas M ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

22q13; Phelan McDermid Syndrome; Shank2; Shank3; Zn2+

Indexed keywords

POSTSYNAPTIC RECEPTOR; PROSAP PROTEIN; SCAFFOLD PROTEIN; SHANK PROTEIN; UNCLASSIFIED DRUG; ZINC ION;

ARTICLE; AUTISM; CELL STRUCTURE; DENDRITIC SPINE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; HUMAN; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SYNAPTIC INHIBITION; SYNAPTIC POTENTIAL;

22Q13; PHELAN MCDERMID SYNDROME; SHANK2; SHANK3; ZN2+;

ANIMALS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; HUMANS; MUTATION; NERVE TISSUE PROTEINS; POST-SYNAPTIC DENSITY; SYNAPTIC TRANSMISSION; ZINC;

EID: 84891902286     PISSN: 19328451     EISSN: 10974695     Source Type: Journal    
DOI: 10.1002/dneu.22089     Document Type: Article

References (87)

1. Adlard PA, Parncutt JM, Finkelstein DI, Bush AI. 2010. Cognitive loss in zinc transporter-3 knock-out mice: A phenocopy for the synaptic and memory deficits of Alzheimer's disease? J Neurosci 30(5):1631-1636.
2. Andrews GK. 2000. Regulation of metallothionein gene expression by oxidative stress and metal ions. Biochem Pharmacol 59(1):95-104.
3. Andrews GK. 2001. Cellular zinc sensors: MTF-1 regulation of gene expression. Biometals 14(3-4):223-237.
4. Arons MH, Thynne CJ, Grabrucker AM, Li D, Schoen M, Cheyne JE, Boeckers TM et al. 2012. Autism associated mutations in ProSAP2/Shank3 impair synaptic transmission and neurexin-neuroligin mediated transsynaptic signaling. J. Neurosci 32(43):14966-14978.
5. Assaf SY, Chung SH. 1984. Release of endogenous Zn2+ from brain tissue during activity. Nature 308(5961):734-736.
6. Aviv T, Lin Z, Ben-Ari G, Smibert CA, Sicheri F. 2006. Sequence-specific recognition of RNA hairpins by the SAM domain of Vts1p. Nat Struct Mol Biol 13:168-176.
7. Baron MK, Böckers TM, Vaida B, Faham S, Gingery M, Sawaya MR, Salyer D, et al. 2006. An architectural framework that may lie at the core of the postsynaptic density. Science 311(5760):531-535.
8. Berkel S, Marshall CR, Weiss B, Howe J, Roeth R, Moog U, Endris V, et al. 2010. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet 42(6):489-491.
9. Besser L, Chorin E, Sekler I, Silverman WF, Atkin S, Russell JT, Hershfinkel M. 2009. Synaptically released zinc triggers metabotropic signaling via a zinc-sensing receptor in the hippocampus. J Neurosci 29(9):2890-2901.
10. Bitanihirwe BK, Cunningham MG. 2009. Zinc: The brain's dark horse. Synapse 63(11):1029-1049.
11. Boeckers TM, Kreutz MR, Winter C, Zuschratter W, Smalla KH, Sanmarti-Vila L, Wex H, et al. 1999. Proline-rich synapse-associated protein-1/cortactin binding protein 1 (ProSAP1/CortBP1) is a PDZ-domain protein highly enriched in the postsynaptic density. J Neurosci 19(15):6506-6518.
12. Boeckers TM, Bockmann J, Kreutz MR, Gundelfinger ED. 2002. ProSAP/Shank proteins - A family of higher order organizing molecules of the postsynaptic density with an emerging role in human neurological disease. J Neurochem 81(5):903910.
13. Boeckers TM, Liedtke T, Spilker C, Dresbach T, Bockmann J, Kreutz MR, Gundelfinger ED. 2005. C-terminal synaptic targeting elements for postsynaptic density proteins ProSAP1/Shank2 and ProSAP2/Shank3. J Neurochem 92(3):519-524.
14. Bonaglia MC, Giorda R, Borgatti R, Felisari G, Gagliardi C, Selicorni A, Zuffardi O. 2001. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am J Hum Genet 69:261-268.
15. Bourgeron T. 2009. A synaptic trek to autism. Curr Opin Neurobiol 19 (2):231-234.
16. Bozdagi O, Sakurai T, Papapetrou D, Wang X, Dickstein DL, Takahashi N, Kajiwara Y, et al. 2011. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol Autism 1:15.
17. Cole TB, Wenzel HJ, Kafer KE, Schwartzkroin PA, Palmiter RD. 1999. Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc Natl Acad Sci USA 96(4):1716-21.
18. Curtis LT, Patel K. 2008. Nutritional and environmental approaches to preventing and treating autism and attention deficit hyperactivity disorder (ADHD): A review. J Altern Complement Med 14(1):79-85.
19. De Rycker M, Price CM. 2004 Tankyrase polymerization is controlled by its sterile a motif and poly(ADP-ribose) polymerase domains. Mol Cell Biol 24:9802-9812.
20. Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, et al. 2007. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 39(1):25-27.
21. Erickson JC, Masters BA, Kelly EJ, Brinster RL, Palmiter RD. 1995. Expression of human metallothionein-III in transgenic mice. Neurochem Int 27 (1):35-41.
22. Erickson JC, Hollopeter G, Thomas SA, Froelick GJ, Palmiter RD. 1997. Disruption of the metallothionein-III gene in mice: Analysis of brain zinc, behavior, and neuron vulnerability to metals, aging, and seizures. J Neurosci 17(4):1271-1281.
23. Faber S, Zinn GM, Kern JC, Kingston HM. 2009. The plasma zinc/serum copper ratio as a biomarker in children with autism spectrum disorders. Biomarkers 14(3):171-180.
24. Fredericksen CJ, Koh JY, Bush AI. 2005. The neurobiology of zinc in health and disease. Nat Rev Neurosci 6:449-462.
25. Gauthier J, Spiegelman D, Piton A, Lafrenière RG, Laurent S, St-Onge J, Lapointe L, et al. 2009. Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet 150B(3):421-424.
26. Golub MS, Keen CL, Gershwin ME, Hendrickx AG. 1995. Developmental zinc deficiency and behavior. J Nutr 125(8):2263-2271.
27. Grabrucker AM. 2012. Environmental factors in autism. Front Psych 3:118.
28. Grabrucker AM, Garner CC, Boeckers TM, Bondioli L, Ruozi B, Forni F, Vandelli MA, et al. 2011c. Development of novel Zn2+ loaded nanoparticles designed for cell-type targeted drug release in CNS neurons: In vitro evidences. Plos One 6(3):e17851.
29. Grabrucker AM, Knight MJ, Proepper C, Bockmann J, Joubert M, Rowan M, Nienhaus GU, et al. 2011b. Concerted action of zinc and ProSAP/Shank in synaptogenesis and synapse maturation. EMBO J. 30(3):569-581.
30. Grabrucker AM, Rowan M, Garner CC. 2011d. Brain-delivery of Zinc-ions as potential treatment for neurological diseases. Drug Deliv Lett 1(1):13-23.
31. Grabrucker AM, Schmeisser MJ, Schoen M, Boeckers TM. 2011a. Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies. Trends Cell Biol 21(10):594-603.
32. Grabrucker S, Jannetti L, Eckert M, Gaub S, Chhabra R, Pfaender S, Mangus K, et al. 2013. Zinc deficiency dysregulates the synaptic ProSAP/Shank scaffold and might contribute to autism spectrum disorders. Brain [in press].
33. Gundelfinger ED, Boeckers TM, Baron MK, Bowie JU. 2006. A role for zinc in postsynaptic density asSAMbly and plasticity? Trends Biochem Sci 31:366-373.
34. 2+ and zinc in the rat. J Inorg Biochem 11 (1):57-66.
35. Hagerman R, Hoem G, Hagerman P. 2010. Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol Autism 1(1):12.
36. Hayashi MK, Tang C, Verpelli C, Narayanan R, Stearns MH, Xu RM, Li H, et al. 2009. The postsynaptic density proteins Homer and Shank form a polymeric network structure. Cell 137(1):159-171.
37. Howell GA, Welch MG, Frederickson CJ. 1984. Stimulation-induced uptake and release of zinc in hippocampal slices. Nature 308(5961):736-738.
38. Huang YZ, Pan E, Xiong ZQ, McNamara JO. 2008. Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron 57:546-558.
39. Huster D. 2010. Wilson disease. Best Pract Res Clin Gastroenterol 24(5):531-539.
40. Jackson KA, Valentine RA, Coneyworth LJ, Mathers JC, Ford D. 2008. Mechanisms of mammalian zinc-regulated gene expression. Biochem Soc Trans 36(Pt 6):1262-1266.
41. Jan HH, Chen IT, Tsai YY, Chang YC. 2002. Structural role of zinc ions bound to postsynaptic densities. J Neurochem 83:525.
42. Jen M, Yan AC. 2010. Syndromes associated with nutritional deficiency and excess. Clin Dermatol 28(6):669-685.
43. Koumura A, Kakefuda K, Honda A, Ito Y, Tsuruma K, Shimazawa M, Uchida Y, et al. 2009. Metallothionein-3 deficient mice exhibit abnormalities of psychological behaviors. Neurosci Lett 467(1):11-14.
44. Lakshmi Priya MD, Geetha A. 2011. Level of trace elements (copper, zinc, magnesium and selenium) and toxic elements (lead and mercury) in the hair and nail of children with autism. Biol Trace Elem Res 142(2):148-158.
45. Levy D, Ronemus M, Yamrom B, Lee YH, Leotta A, Kendall J, et al. 2011. Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron 70(5):886-897.
46. Li X, Zou H, Brown WT. 2012. Genes associated with autism spectrum disorder. Brain Res Bull 88(6):543-552.
47. 2+. J Neurosci 21:8015-8025.
48. Lynch MA. 2004. Long-term potentiation and memory. Physiol Rev 84(1):87-136.
49. Manning MA, Cassidy SB, Clericuzio C, Cherry AM, Schwartz S, Hudgins L, Enns GM, et al. 2004. Terminal 22q deletion syndrome: A newly recognized cause of speech and language disability in the autism spectrum. Pediatrics 114:451-457.
50. Martel G, Hevi C, Friebely O, Baybutt T, Shumyatsky GP. 2010. Zinc transporter 3 is involved in learned fear and extinction, but not in innate fear. Learn Mem 17(11):582-590.
51. Meyer G, Varoqueaux F, Neeb A, Oschlies M, Brose N. 2004. The complexity of PDZ domain-mediated interactions at glutamatergic synapses: A case study on neuroligin. Neuropharmacology 47:724-733.
52. Moessner R, Marshall CR, Sutcliffe JS, Skaug J, Pinto D, Vincent J, Zwaigenbaum L, et al. 2007. Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 81(6):1289-1297.
53. Naisbitt S, Kim E, Tu JC, Xiao B, Sala C, Valtschanoff J, Weinberg RJ, et al. 1999. Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron 23:569-582.
54. Nuttall JR, Oteiza PI. 2012. Zinc and the ERK kinases in the developing brain. Neurotox Res 21(1):128-141.
55. Oberstrass FC, Lee A, Stefl R, Janis M, Chanfreau G, Allain FH. 2006. Shape-specific recognition in the structure of the Vts1p SAM domain with RNA. Nat Struct Mol Biol 13:160-167.
56. O'Roak BJ, Deriziotis P, Lee C, Vives L, Schwartz JJ, Girirajan S, Karakoc E, et al. 2011. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet 43(6):585-589.
57. Park JD, Liu Y, Klaassen CD. 2001. Protective effect of metallothionein against the toxicity of cadmium and other metals(1). Toxicology 163(2-3):93-100.
58. Pérez-Clausell J, Danscher G. 1985. Intravesicular localization of zinc in rat telencephalic boutons. A histochemical study. Brain Res 337(1):91-98.
59. Pfeiffer CC, Braverman ER. 1982. Zinc, the brain and behavior. Biol Psychiatry 17(4):513-532.
60. Phelan MC, Rogers RC, Saul RA, Stapleton GA, Sweet K, McDermid H, Shaw SR, et al. 2001. Research Review: 22q13 Deletion Syndrome. Am J Med Genet 101:91-99.
61. Phelan MC. 2008. Deletion 22q13.3 syndrome. Orphanet J Rare Dis 273(1):14.
62. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, Conroy J, et al. 2010. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 466(7304):368-72.
63. Qiao F, Song H, Kim CA, Sawaya MR, Hunter JB, Gingery M, Rebay I, et al. 2004. Derepression by depolymerization; structural insights into the regulation of Yan by Mae. Cell 118:163-173.
64. Qiao F, Bowie JU. 2005. The many faces of SAM. Sci STKE 2005, re7.
65. Qiao F, Harada B, Song H, Whitelegge J, Courey AJ, Bowie JU. 2006. Mae inhibits Pointed-P2 transcriptional activity by blocking its MAPK docking site. EMBO J 25:70-79.
66. Roussignol G, Ango F, Romorini S, Tu JC, Sala C, Worley PF, Bockaert J, et al. 2005. Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. J Neurosci 25:3560-3570.
67. Sanders SJ, Murtha MT, Gupta AR, Murdoch JD, Raubeson MJ, Willsey AJ, Ercan-Sencicek AG, et al. 2012. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 485 (7397):237-241.
68. Sandstead HH, Strobel DA, Logan GM, Marks EO, Jacob RA. 1978. Zinc deficiency in pregnant rhesus monkeys: Effects on behavior of infants. Am J Clin Nutr 31(5):844-849.
69. Sato D, Lionel AC, Leblond CS, Prasad A, Pinto D, Walker S, O'Connor I, et al. 2012. SHANK1 deletions in males with autism spectrum disorder. Am J Hum Genet 90(5):879-887.
70. Schmeisser MJ, Ey E, Wegener S, Bockmann J, Stempel AV, Kuebler A, Janssen AL, et al. 2012. Autistic-like behaviours and hyperactivity in mice lacking ProSAP1/Shank2. Nature 486(7402):256-260.
71. Serajee FJ, Nabi R, Zhong H, Huq M. 2004. Polymorphisms in xenobiotic metabolism genes and autism. J Child Neurol 19(6):413-417.
72. Shankar AH, Prasad AS. 1998. Zinc and immune function: The biological basis of altered resistance to infection. Am J Clin Nutr 68:447-463.
73. Sindreu CB, Varoqui H, Erickson JD, Pérez-Clausell J. 2003. Boutons containing vesicular zinc define a subpopulation of synapses with low AMPAR content in rat hippocampus. Cereb Cortex 13(8):823-829.
74. Sindreu C, Palmiter RD, Storm DR. 2011. Zinc transporter ZnT-3 regulates presynaptic Erk1/2 signaling and hippocampus-dependent memory. Proc Natl Acad Sci USA 108(8):3366-3370.
75. Sindreu C, Storm DR. 2011. Modulation of neuronal signal transduction and memory formation by synaptic zinc. Front Behav Neurosci 5:68.
76. Song H, Nie M, Qiao F, Bowie JU, Courey AJ. 2005. Antagonistic regulation of Yan nuclear export by Mae and Crm1 may increase the stringency of the Ras response. Genes Dev 19:1767-1772.
77. Trabacca A, Losito L, De Rinaldis M, Gennaro L. 2011. Congenital hypotonia in a child with a de novo 22q13 monosomy and 2pter duplication: A clinical and molecular genetic study. J Child Neurol 26(2):235-238.
78. Tuchman R, Cuccaro M. 2011. Epilepsy and autism: Neurodevelopmental perspective. Curr Neurol Neurosci Rep 11(4):428-434.
79. Verpelli C, Dvoretskova E, Vicidomini C, Rossi F, Chiappalone M, Schoen M, Di Stefano B, et al. 2011. Importance of shank3 in regulating metabotropic glutamate receptor 5 (mGluR5) expression and signaling at synapses. J Biol Chem 286(40):34839-34850.
80. Vincent SR, Semba K. 1989. A heavy metal marker of the developing striatal mosaic. Brain Res Dev Brain Res 45(1):155-159.
81. Walsh WJ, Usman A, Tarpey J. 2001. Disordered metal metabolism in a large autism population, Proceedings of the Amer Psych Assn; New Research: Abstract NR109, New Orleans.
82. Walsh WJ, Usman A, Tarpey J, Kelly T. 2002. Metallothionein and Autism, 2nd ed. Naperville, IL: Pfeiffer Treatment Center.
83. Wang X, Zhou B. 2010. Dietary zinc absorption: A play of Zips and ZnTs in the gut. IUBMB Life 62(3):176-82.
84. Wilson HL, Wong ACC, Shaw SR, Tse W-Y, Stapleton GA, Phelan MC, Hu S, et al. 2003. Molecular characterization of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Gen 40:575-584.
85. Wimmer U, Wang Y, Georgiev O, Schaffner W. 2005. Two major branches of anti-cadmium defense in the mouse: MTF-1/metallothioneins and glutathione. Nucleic Acids Res 33 (18):5715-5727.
86. Wong AC, Bell CJ, Dumanski JP, Budarf ML, McDermid, HE. 1995. Molecular characterization of a microdeletion at 22q13.3. Am J Hum Genet 57:A130.
87. Yasuda H, Yoshida K, Yasuda Y, Tsutsui T. 2011. Infantile zinc deficiency: Association with autism spectrum disorders. Sci Rep 1:129.